Hybrid proteins CFP10 and ESAT6. A path from developing a molecule to population screening for TB infection

Abstract

The review presents the history of the creation and mass production of Diaskintest® - a drug for mass screening of the population to detect a tuberculosis infection. The molecule contains two proteins ESAT6 and CFP10 that are only found in virulent Mycobacterium tuberculosis and are absent in the M. bovis BCG vaccine strain. The prognostic value of the drug is determined by the fact that these proteins are secreted by dividing Mycobacterium tuberculosis only, and not by that in a dormant state. Such a genetically engineered product required the creation of high-tech manufacturing facilities for mass production of the drug that would meet the needs of the entire country, which was done in the shortest possible time. This diagnosticum is intended for intracutaneous administration and its administration technique is similar to the Mantoux test, which made the test available for mass use. In preclinical studies, the skin test using Diaskintest® has proved its safety, high specificity and sensitivity. Clinical studies the results of which have been confirmed by broad clinical practice, as well as post-marketing surveillance demonstrated that the test has high specificity, sensitivity, and prognostic value. Mass screening of the child and adolescent population resulted in a sharp decrease in morbidity and an improvement in the structure of clinical forms in patients. Using the test in risk groups in adults makes it possible to identify persons with tuberculosis and those in need of preventive treatment. The Diaskintest® test has proven its effectiveness in clinical practice when used in primary health care.

Keywords:recombinant tuberculous allergen; diaskintest; tuberculosis infection

For citation: Kudlay D.A. Hybrid proteins CFP10 and ESAT6. A path from developing a molecule to population screening for TB infection. Immunologiya. 2021; 42 (2): 166-74. DOI: https://doi.org/10.33029/0206-4952-2021-42-2-166-174 (in Russian)

Funding. The study had no sponsor support.

Conflict of interests. Author declares no conflict of interests.

References

1. Lönnroth K., Castro K., Chakaya J., Chauhan L., Floyd K., Glaziou P., et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010; 375 (9728): 1814–29. DOI: https://doi.org/10.1016/S0140-6736(10)60483-7

2. Consensus meeting report: development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Geneva: World Health Organization, 2017. (WHO/HTM/TB/2017.18). URL: https://creativecommons.org/licenses/by-nc-sa/3.0/igo )

3. Kudlay D. A. Biomarkers and immunological tests. Experimental and clinical parallels of latent tuberculosis infection. Tuberculosis and lung diseases. 2020; 98 (8): 63–74. URL: http://doi.org/10.21292/2075-1230-2020-98-8-63-74 (in Russian)

4. Implementing the end TB strategy: the essentials. World Health Organization. Geneva, 2015(WHO/HTM/TB/2015.31). URL: http://www.who.int/tb/publications/2015/end_tb_essential.pdf?ua=1) (date of access 18 July, 2017)

5. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.

6. Pai M. Innovations in tuberculosis diagnostics: progress and translational challenges. EBioMedicine. 2015; 2 (3): 182–3. DOI: https://doi.org/10.1016/ j.ebiom.2015.01.018

7. Cole S., Brosch R., Parkhill J., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998; 393: 537–44.

8. Mahairas G., Sabo P., Hickey M., et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 1996; 178: 1274–82.

9. Behr M., Wilson M., Gill W., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999; 284: 1520–3.

10. Dillon D., Alderson М., Day Н., et al. Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J. Clin. Microbiol. 2000; 38: 3285–90.

11. Harboe M., Oettinger T., Wiker H., et al. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect. Immun. 1996; 64: 16–22.

12. Arend S., Andersen P., van Meijgaarden K., et al. Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J. Infect. Dis. 2000; 181: 1850–4.

13. Berthet F., Rasmussen P., Rosenkrands I., et al. Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology. 1998; 144 (11): 3195–203.

14. Kiselev V.I., Paltsev M.A., Perelman M.I., Baranovsky P.M. Scientific substantiation and creation of the recombinant tuberculosis allergen CFP10-ESAT6 (drug «Diaskintest»). In.: Skin Test with the Drug «Diaskintest» – New Opportunities for the Identification of Tuberculosis Infection. M.A. Pal’tsev (ed.). 2nd ed., revised and additional. Moscow: Shiko, 2011: 73–87. (in Russian)

15. Kiselev V.I., Severin E.S., Perel’man M.I., Pal’tsev M.A. New biotechnological solutions in the diagnosis and prevention of tuberculosis infection. Bulletin of the Research Institute of Molecular Medicine. 2005; 5: 37–46. (in Russian)

16. Kiselev V.I., Baranovsky P.M., Pupyshev S.A., et al. New skin test for the diagnosis of tuberculosis based on the recombinant protein ESAT-CFP. Molecular Medicine. 2008; 4: 4–6. (in Russian)

17. Kiselev V.I., Pal’tsev M.A. Fusion protein CFP10-ESAT6, inducing a delayed-type hypersensitivity reaction against M. tuberculosis, a chimeric nucleic acid encoding it and a recombinant plasmid expression vector containing it, a method for producing a fusion protein and a dosage form for intradermal injection based on it. Patent RF No. 2360926; 2008. (in Russian)

18. Brodin P., de Jonge M.I., Majlessi L., et al. Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. J. Biol. Chem. 2005; 280 (40): 33 953–9. DOI: https://doi.org/10.1074/jbc.m503515200

19. Levi D.T., Rukhamina M.L. Preclinical studies of the drug «Diaskintest». In: Skin Test with the Drug «Diaskintest» – New Opportunities for the Identification of Tuberculosis Infection. M.A. Pal’tsev (ed.). 2nd ed., revised and additional. Moscow: Shiko, 2011: 65–79. (in Russian)

20. Bocharova I.V., Demin A.V. Preclinical studies of the specific activity of the drug «Diaskintest». In. Skin Test with the Drug «Diaskintest» – New Opportunities for the Identification of Tuberculosis Infection. M.A. Pal’tsev (ed.). 2nd ed., revised and additional. Moscow: Shiko, 2011: 114–25. (in Russian)

21. Kiselev V.I., Baranovsky P.M., Rudykh I.V., et al. Clinical studies of the new Diaskintest® skin test for the diagnosis of tuberculosis. Tuberculosis problems. 2009; (2): 1–8. (in Russian)

22. Order of the Ministry of Health and Social Development of Russia No. 855 of 29.10.2009. «On Amendments to Appendix No. 4 to Order No. 109 of the Ministry of Health of the Russian Federation of March 21, 2003». (in Russian)

23. Slogotskaya L.V., Bogorodskaya E.M., Sinitsyn M.V., Kudlay D.A., Shamuratova L.F., Sevostyanova T.A. Screening of tuberculosis infection with various options for the use of recombinant tuberculosis allergen in children and adolescents in Moscow. Pediatrics. Journal named after G.N. Speransky. 2020; 99 (2): 136–46. (in Russian)

24. Slogotskaya L.V., Bogorodskaya E.M., Shamuratova L.F., Sevost’yanova T.A. Efficiency of screening for tuberculosis infection in children and adolescents in Moscow in 2019 based on the new procedure for using the intradermal test with tuberculosis recombinant allergen (ESAT-6/CFP-10). Tuberculosis and lung diseases. 2021; 99 (1): 15–25. DOI: https://doi.org/10.21292/2075-1230-2021-99-1-15-25 (in Russian)

25. Aksenova V.A., Vasilyeva I.A., Kasaeva T.Ch., Samoilova A.G., Pshenichnaya N.Yu., Tyulkova T.E. Latent tuberculosis infection in children and adolescents in Russia. Int. J. Infect. Dis. 2020; 92S: S26–30. DOI: https://doi.org/10.1016/j.ijid.2020.02.038

26. Aksenova V.A., Baryshnikova L.A., Klevno N.I., Kudlay D.A. Screening for tuberculosis infection in children and adolescents in Russia – past, present, future. Tuberculosis and lung diseases. 2019; 97 (9): 59–67. DOI: http://doi.org/10.21292/2075-1230-2019-97-9-59-66 (in Russian)

27. Kudlay D.A., Starshinova A.A., Dovgalyuk I.F. Recombinant tuberculosis allergen: 10-year experience of using the test in children and adolescents in the Russian Federation (meta-analysis data). Pediatriya. Pediatrics. Journal named after G.N. Speransky. 2020; 99 (3): 121–9. (in Russian)

28. Bogorodskaya E.M., Slogotskaya L.V., Belilovsky E.M., Roshchupkina O.M. Latent tuberculosis infection in risk groups in the adult population of the city of Moscow, 2012–2016. Tuberculosis and socially significant diseases. 2017; 2: 10–5. (in Russian)

29. Order of the Ministry of Health of the Russian Federation of 29.12.2014 No. 951. «On approval of methodological recommendations for improving the diagnosis and treatment of tuberculosis of the respiratory system». Moscow: Ministry of Health of Russia, 2014. (in Russian)

30. Order of the Ministry of Health of the Russian Federation No. 124n of 21.03.2017 «On approval of the procedure and terms of preventive medical examinations of citizens in order to detect tuberculosis». (in Russian)

31. Slogotskaya L.V., Senchikhina O.Yu., Nikitina G.V., Bogorodskaya E.M. The effectiveness of a skin test with a recombinant tuberculosis allergen in detecting tuberculosis in children and adolescents in Moscow in 2013. Pediatric Pharmacology. 2015; 1: 99–103. (in Russian)

32. Aksenova V.A., Baryshnikova L.A., Klevno N.I., Sokol’skaya E.A., Dolzhenko E.N., Shuster A.M., et al. New opportunities for screening and diagnostics of various manifestations of tuberculosis infection in children and adolescents in Russia. Issues of modern pediatrics. 2011; 4: 16–22. (in Russian)

33. Dolzhenko E.N., Sheykis E.G., Seregina I.V. Diagnostic capabilities of recombinant tuberculosis allergen in the screening diagnosis of tuberculosis infection in adolescent children in the Ryazan region. Tuberculosis and lung diseases. 2015; 6: 56–7. (in Russian)

34. Bogorodskaya E.M., Belilovsky E.M., Puchkov K.G., Senchikhina O.Yu., Shamuratova L.F. The incidence of tuberculosis in young children in Moscow and factors affecting it. Tuberculosis and socially significant diseases. 2014; 5: 16–23. (in Russian)

35. Borisov S.E., Lukina G.V., Slogotskaya L.V., et al. Screening and monitoring of tuberculosis infection in rheumatological patients receiving genetically engineered biological preparations. Tuberculosis and lung diseases. 2011; 6: 42–50. (in Russian)

36. Frolova K.S., Borisov S.E., Slutskaya O.M. Tuberculosis in patients with inflammatory diseases treated with TNF-alpha inhibitors. Tuberculosis and socially significant diseases. 2018; 2: 31–41. (in Russian)

37. Cardona P. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection. 2009; 37 (2): 80–6.

38. Fox W., Ellard G., Mitchison D. Studies on the treatment of tuberculosis under taken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int. J. Tuberc. Lung. Dis. 1999; 3: 231–79.

39. Mitchison D. Basic mechanisms of chemotherapy. Chest. 1979; 76 (6): 771–81.

40. Sinitsyn M.V., Bogorodskaya E.M., Ayusheeva L.B., Belilovsky E.M. Latent tuberculosis infection among HIV-infected persons in the city of Moscow. Tuberculosis and socially significant diseases. 2017; 2: 42–9. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»